The syndrome of primary aldosteronism is characterized by definition by an autonomous hypersecretion of aldosterone (aldo), i.e, independent from the known regulatory factors. In fact, plasma renin activity is suppressed. ACTH levels are normal and serum K potassium levels are low. However, there are two major subtypes of primary hyperaldosteronism (PHA) with different characteristics: in patients with aldosteroneproducing adenoma (APA) aldosterone secretion is unresponsive to angiotensin I1 stimulation, but is still modulated by ACTH; this is reflected in the circadian rhythm of plasma aldosterone levels which parallel cortisol levels, while aldosterone does not respond to upright posture. Furthermore, a transient decrease of aldosterone levels can be obtained by a short-term dexamethasone administration. In the other subtype of PHA, idiopathic hyperaldosteronism (IHA), a certain degree of sensitivity to the renin-angiotensin system persists, as demonstrated by the absence of diurnal rhythmicity, the clear-cut increase of plasma aldosterone after postural stimulation and exogenous angiotensin II administration and occasionally even a decrease of aldosterone after captopril administration (I).
This rather schematic distinction between the two main forms of primary aldosteronism is today challenged by the description of a certain number of cases of so-called renin-responsive aldosterone-producing adenoma which show an in vivo response to posture and angiotensin 11. According to Gordon et al. these tumours present with characteristic histological findings (2) . Furthermore, another unusual subgroup of patients with adrenal hyperplasia behave as far as the functional tests are concerned as patients harbouring an aldosterone-producing tumour. They have been termed by Biglieri et al., as having primary adrenal hyperpIasia, and are insensitive to angiotensin I1 (3). Finally, the molecular genetics of a hereditary form of hyperaldosteronism, called glucocorticoid-remediable hyperaldosteronisrn, has been recently clarified (4) . The disease, which is due to a chimeric gene comprised of the regulatory region of 11 beta hydroxylase (ACTH dependent) and the coding region of aldosterone synthase, results in a chronic ACTH-stimuIated aldosterone hypersecretion and in an unresponsiveness to angiotensin 11.
As demonstrated in the paper by Yagi et al, in this issue, these functional characteristics are far from being strict ( 5 ) , since long-term treatment with spironolactone may profoundly affect the mechanisms of aldosterone regulation in the different forms of primary aldosteronism. Our group has previousIy shown in patients with aldosterone-producing adenoma that a short-term treatment with spironolactone reduces serum aldosterone levels without restoring normal renin Ievels. This is probably due to the direct inhibiting effect on steroidogenic enzymes. A more prolonged treatment is characterized by an increase in serum renin Ievels and a return of aldosterone to pretreatment Ievels (6) . Even after a much more prolonged period of observation, Kater and Biglieri have shown that as spironolactone-induced natriuresis progresses and extracellular volume expansion decreases, plasma renin activity rises but aldosterone levels remain within the baseline values, and do not increase after upright posture (7) . However, when challenged with a more potent stimulus, such as the furosemide test used by Yagi, the zona glomeruIosa of the normal adrenal and/or the adenoma again become sensitive to angiotensin I1 stimulation. When the ACTH drive is excluded by dexamethasone, this sensitivity becomes even greater. Contrary to this, the sensitivity to ACTH was greater in untreated patients than in those under chronic spironolactone treatment. Thus under conditions of continuous renin stimulation, the functional characteristics of APA resemble those of idiopathic hyperaldosteronism. In the latter case, however, the control of aldosterone secretion by angiotensin I1 becomes even more apparent under spironolactone; with increasing renin activity and concomitant increase (paradoxical increase) in aldosterone levels. On the basis of this different behaviour, baseline aldosterone levels under chronic spironolactone treatment were suggested by Kater and Biglieri as an additional criterion for the differential diagnosis between the two main subtypes of primary aldosteronism. It is likely that in APA aldosterone levels reflect the balance between the direct inhibitory effect of spironolactone on the tumour and the action of angiotensin I1 on the adjacent and controlateral adrenal. However, it cannot be ruled out that even the adenoma can become responsive to angiotensin 11. In fact, in vitro, these cells may respond to angiotensin 11, although with a lower sensitivity in aldosteronoma (8) . Angiotensin I1 binding sites and angiotensin type I receptors mRNA have been found in similar or even greater amounts to normal adrenal tissue by our group and by Saruta et al. (9. 10) . Thus, the in vivo and in vitro reduced response of these tumoral cells to angiotensin I1 could be due to a post-receptor mechanism rather than to an abnormality of the receptor itself. Molecular biology studies are in progress in several laboratories with the aim of possibly elucidating the intracellular mechanisms (mutations of G protein, allelic losses, changes in gene expression of steroidogenic enzymes, etc.) which might be involved in the pathogenesis of different types of adrenal tumours. 
